Upexi Faces Nasdaq Delisting Risk Over Shareholder Approval Violations; Joins Russell Microcap Index
Summary
Upexi received a Nasdaq non-compliance notice for issuing convertible notes without shareholder approval, risking delisting, even as it announced inclusion in the Russell Microcap Index.
Key Events
-
Nasdaq Non-Compliance Notice
Upexi received a letter from Nasdaq for non-compliance with Listing Rule 5635(a), citing the issuance of approximately $187 million in convertible notes without required shareholder approval.
-
Potential Delisting Risk
The convertible notes were convertible into 20% or more of the company's pre-transaction shares. Upexi has until August 10, 2026, to submit a plan to regain compliance, with potential delisting if the plan is not accepted or compliance is not achieved.
-
Russell Microcap Index Inclusion
The company announced its addition to the Russell Microcap® Index, effective June 29, 2026, which is expected to increase visibility among institutional investors and index funds.
Analysis
Upexi received a notice from Nasdaq regarding non-compliance with listing rules, specifically for issuing approximately $187 million in convertible notes without shareholder approval. These notes could convert into over 20% of the company's shares, posing a significant governance issue and potential delisting risk. While the company has 45 days to submit a compliance plan, the threat to its Nasdaq listing is a critical concern. This negative development overshadows the positive news of the company's inclusion in the Russell Microcap Index, which typically enhances institutional visibility and liquidity.
At the time of this filing, UPXI was trading at $0.81 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $58.5M. The 52-week trading range was $0.54 to $10.62. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.